- Home
- RLGT vs PBYI Comparison
RLGT vs PBYI Comparison
Compare RLGT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLGT | PBYI |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 291.6M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RLGT | PBYI |
|---|---|---|
| Price | $6.74 | $5.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.00 | $7.00 |
| AVG Volume (30 Days) | 154.2K | ★ 402.3K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.35 | 59.87 |
| EPS | 0.31 | ★ 0.74 |
| Revenue | ★ $925,786,000.00 | $211,995,000.00 |
| Revenue This Year | $3.77 | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $21.55 | ★ $7.87 |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $5.44 | $2.58 |
| 52 Week High | $7.94 | $6.12 |
Technical Indicators
Market Signals| Indicator | RLGT | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 67.35 |
| Support Level | $6.67 | $4.84 |
| Resistance Level | $6.86 | $5.11 |
| Average True Range (ATR) | 0.16 | 0.20 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 77.91 | 96.24 |
Price Performance
Historical ComparisonAbout RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.